TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Sugammadex/Neostigmine and Liver Transplantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* American Society of Anesthesiology status (ASA) III~* Ability to give a written informed consent~* Liver transplantation~Exclusion Criteria:~* Any allergy to medications involved in the study~* Any disease involving neuromuscular transmission~* Any therapy with toremifene, flucloxacillin or fusidic acid~* Renal disease with glomerular filtration rate less than 30 ml/min/1.73m2~* Hyperthermia maligna~* Anticonceptional therapy~* Pregnancy~* Core body temperature less than 35°C or skin temperature less than 32°C at the end of surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- sugammadex (Type: ACTIVE_COMPARATOR): at the end of surgery administration of 2 mg/kg of sugammadex after the third T2 twitch at Train of Four (TOF) stimulation
- neostigmine (Type: ACTIVE_COMPARATOR): at the end of surgery administration of 50 mcg/kg of neostigmine after the third T2 twitch at Train of Four (TOF) stimulation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sensor and Software Use for Improved Glucose Control in MDI Managed Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years and over~* Type 1 diabetes on MDI with bolus injections for \>6 months prior to study enrolment or Type 2 diabetes treated with 2 or more insulin injections daily.~* In the investigator's opinion, thought technically capable of using FreeStyle Navigator GM System device.~* HbA1c between 7.5 and 12.0% (58 to 108 mmol/mol) for previous test obtained within 6 months prior to point of enrolment~Exclusion Criteria:~* Concomitant disease or condition that may compromise patient safety, including unstable coronary heart disease, cystic fibrosis, serious psychiatric disorder, or any uncontrolled chronic medical condition~* Female subject is pregnant or planning to become pregnant within the planned study duration. Subjects who become pregnant during the study will be discontinued from the study.~* Currently using / has previously used a Continuous Glucose Monitoring System within the last 6 months.~* Currently using Continuous Subcutaneous Insulin Infusion (CSII)~* Currently using basal/long acting insulin only.~* Participating in another study of a glucose monitoring device / drug that could affect glucose measurements / management~* Known allergy to medical grade adhesives~* In the investigators opinion is unsuitable to participate due to any other cause/reason.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CGM - intervention arm (Type: EXPERIMENTAL): Following a 14 day masked (baseline) period using the FreeStyle Navigator subjects will wear an unmasked FreeStyle Navigator with the glucose alarms switched off.
- SMBG - Control arm (Type: ACTIVE_COMPARATOR): Following a 14 day masked ( baseline) period using the FreeStyle Navigator subjects will manage their blood glucose with a standard SMBG and use a FreeStyle Navigator masked for a 14 day period at the end of the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Desmopressin Melt: Impact on Sleep and Daytime Functioning

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* New patient~* age 6 to 16 years~* monosymptomatic nocturnal enuresis, nocturnal polyuria and sleep problems~Exclusion Criteria:~* mental retardation~* autism spectrum disorders~* daytime incontinence resistant to therapy~* dysfunctional voiding~* poor therapy-compliance~* diuretics, antihypertensives, uropathy, renal abnormalities

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- Desmopressin lyophilisate (Melt) (Type: EXPERIMENTAL): Patients receiving Desmopressin lyophilisate (Melt).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Reducing High School Athletes' Prescription Opioids Misuse and Diversion Through the Student Athlete Wellness Portal

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* English-speaking male and female adolescents~* Ages 13-19~* Attending middle or high school~* Playing at last one interscholastic sport~* Parental consent~Exclusion Criteria:~* No parental consent~* outside the age range~* not participating in interscholastic sports~* not in middle or high school~* participated in the Phase I research

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 19 Years
- Healthy Volunteers: t

Study Arms:
- Student Athlete Wellness Portal (Type: EXPERIMENTAL): Web-based intervention that illustrates opioid misuse and diversion resistance strategies.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Naproxen Capsules to Treat Dental Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is male or female between 18 and 50 years of age~* For women of child-bearing potential: a woman who is not pregnant and not nursing, and who is practicing an acceptable method of birth control~* Patient requires extraction of 2 or more third molars~* Patient must be willing to stay at the study site overnight~Exclusion Criteria:~* Patient has hypersensitivity, allergy, or clinically significant intolerance to any medications to be used in the study, or related drugs~* Patient has a current disease or history of a disease that will impact the study or the patient's well-being~* Patient has used or intends to use any of the medications that are prohibited by the protocol~* Patient has a history of drug or alcohol abuse or dependence, or patient has a positive urine drug screen or alcohol breathalyzer test~* Patient has taken another investigational drug within 30 days prior to screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Naproxen Test (lower dose) (Type: EXPERIMENTAL): 200-mg
- Naproxen Test (upper dose) (Type: EXPERIMENTAL): 400-mg (2 x 200-mg)
- Naprosyn 250 mg (Type: ACTIVE_COMPARATOR): None
- Naprosyn 500 mg (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Augmentation of Treatment-Resistant Depression With An Analog of the Neuroactive Steroid Allopregnanolone

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Female, age 50-75~2. Postmenopausal~3. Major Depressive Disorder~4. Currently treated with SSRI or SNRI at adequate dose~Exclusion Criteria:~1. Serious suicide or homicide risk~2. Unstable medical illness~3. Substance use disorder~4. Psychosis~5. Use of hormones (estrogens, androgens or related hormones)~6. History of hormone responsive cancer~7. Receiving strong CYP3A4 inducers or inhibitors or who intend to consume grapefruit products regularly during the study~8. Alanine aminotransferase (ALT) or creatinine \> 3x upper limit of normal

- Gender: FEMALE
- Minimum Age: 50 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Ganaxolone (Type: EXPERIMENTAL): Participants received ganaxolone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of SureCALL® EMG Labor Monitor® and Tocodynamometer to Intrauterine Pressure Catheter Measurement (IUPC) Measurement in Pregnant Women

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Singleton Pregnancy~* Indicated for IUPC~* Gestational ages from 37 to 41 weeks~* Informed consent required~Exclusion Criteria:~* Multifetal Pregnancy~* Not Indicated for IUPC~* Gestation ages below 37 or above 41 weeks~* Informed consent not given

- Gender: FEMALE
- Minimum Age: 15 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Pregnant, In Labor (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of NN1250 With Sitagliptin in Subjects With Type 2 Diabetes Never Treated With Insulin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes (diagnosed clinically) for at least 6 months~* Ongoing treatment with 1 or 2 of the following OADs (metformin, insulin secretagogue (sulphonylurea or glinides) or pioglitazone) in any combination with unchanged dosing for at least 3 months prior to Visit 1 with the minimum doses stated: -Metformin: alone or in combination (including fixed combination)1500 mg or maximum tolerated dose (at least 1000 mg daily) -Insulin secretagogue (sulfonylurea or glinide): minimum half of the maximal daily dose according to local labelling -Pioglitazone: minimum half of the maximal daily dose according to local labelling or maximum tolerated dose~* Body Mass Index (BMI) below or equal to 40.0 kg/m\^2~* HbA1c 7.5-11.0 % (both inclusive) by central laboratory analysis~Exclusion Criteria:~* Use within the last 3 months prior to Visit 1 of: exenatide, liraglutide, rosiglitazone or acarbose~* Cardiovascular disease, within the last 6 months prior to Visit 1, defined as: stroke; decompensated heart failure New York Heart Association (NYHA) class III or IV; myocardial infarction; unstable angina pectoris; or coronary arterial bypass graft or angioplasty~* Uncontrolled treated/untreated severe hypertension (systolic blood pressure at least 180 millimetre (mm) mercury (Hg) and/or diastolic blood pressure at least 100 mmHg)~* Recurrent severe hypoglycaemia (more than 1 severe hypoglycaemic event during the last 12 months) or hypoglycaemic unawareness as judged by the Investigator or hospitalisation for diabetic ketoacidosis during the previous 6 months~* Pregnancy, breast-feeding, the intention of becoming pregnant or not using adequate~* Cancer and medical history hereof (except basal cell skin cancer or squamous cell skin cancer)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IDeg OD (Type: EXPERIMENTAL): None
- DPP-IV inhibitor (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed adrenocortical carcinoma~  * Newly diagnosed disease within the past 3 weeks~ * Any disease stage allowed~* Lansky performance status 60-100% (for patients ≤ 16 years old)~* Karnofsky performance status 60-100% (for patients \> 16 years old)~* Absolute neutrophil count ≥ 750/mm\^3~* Platelet count ≥ 75,000/mm\^3~* Creatinine clearance or radioisotope glomerular filtration rate ≥ 70 mL/min OR serum creatinine based on age as follows:~  * 0.4 mg/dL (1 month to \< 6 months)~ * 0.5 mg/dL (6 months to \< 1 year of age)~ * 0.6 mg/dL (1 to \< 2 years of age~ * 0.8 mg/dL (2 to \< 6 years of age)~ * 1.0 mg/dL (6 to \< 10 years of age)~ * 1.2 mg/dL (10 to \< 13 years of age)~ * 1.5 mg/dL (male) or 1.4 mg/dL (female) (13 to \< 16 years of age)~ * 1.7 mg/dL (male) or 1.4 mg/dL (female) (≥ 16 years of age)~* Bilirubin ≤ 1.5 times upper limit of normal (ULN)~* AST or ALT \< 2.5 times ULN~* Shortening fraction ≥ 27% by echocardiogram OR ejection fraction ≥ 50% by radionuclide angiogram~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No previous chemotherapy for adrenocortical carcinoma

- Gender: ALL
- Minimum Age: None
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Stratum I (surgery, observation) (Type: EXPERIMENTAL): Patients undergo primary tumor resection and retroperitoneal lymph node sampling followed by observation. Patients who have undergone prior surgery without nodal sampling undergo observation only.
- Stratum II (exploratory surgery, observation) (Type: EXPERIMENTAL): Patients undergo primary tumor resection and extended regional lymph node dissection followed by observation. Patients who have undergone prior surgery with simple resection of the primary tumor undergo exploratory surgery with extended regional lymph node dissection followed by observation.
- Stratum III (chemotherapy, surgery) (Type: EXPERIMENTAL): Patients receive combination chemotherapy with filgrastim (G-CSF) for up to 30 weeks (10 courses) followed by mitotane alone for an additional 2 months. Some patients undergo surgery after chemotherapy course 2 or 4. Some patients undergo additional surgery after finishing all chemotherapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Tolerability Study of BIVV020 in Adults With Cold Agglutinin Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria :~* Male and/or female patients, ≥ 18 years of age with cold agglutinin disease as defined by:~  1. Chronic hemolysis per Investigator's judgement,~ 2. Polyspecific direct antiglobulin test (DAT) positive,~ 3. Monospecific DAT strongly positive for C3d,~ 4. Cold agglutinin (CAg) titer ≥ 64 at 4 C; and,~ 5. IgG DAT ≤1+.~* A hemoglobin level ≤11 mg/dL.~* A total bilirubin level above the normal reference range that is thought to be due to hemolysis.~* Documented vaccinations against encapsulated bacterial pathogens (Neisseria meningitidis, including serogroup B meningococcus and Streptococcus pneumoniae) within five years of screening or willing to complete protocol specified vaccinations.~* Having given written informed consent prior to undertaking any study-related procedure.~Exclusion criteria:~* Cold agglutinin syndrome secondary to infection, rheumatologic disease, or known high grade hematologic malignancy, or known solid organ tumor.~* Clinically relevant infection of any kind within one month preceding screening.~* Treatment with anti-CD20 monotherapy within three months or anti CD20 combination therapies within six months prior to screening.~* Concurrent treatment with systemic immunosuppressive agents targeting B- or T-cell function and/or cytotoxic agents within 3 months prior to screening. Concurrent treatment with other systemic immunosuppressants within 5.5 half-lives of the drug prior to screening.~* Any specific complement system inhibitor within three months prior to screening.~* Concurrent treatment with systemic corticosteroids other than a stable daily dose equivalent to ≤10 mg/day prednisone within three months prior to screening.~* If female, pregnant or lactating.~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BIVV020 IV (Type: EXPERIMENTAL): Single administration dose 1, plus two optional doses of BIVV020 administered intravenously.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Pan Asian Trial Comparing Efficacy and Safety of NN5401 and Biphasic Insulin Aspart 30 in Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female at least 18 years of age (at least 20 years for Japan)~* Type 2 diabetes mellitus (diagnosed clinically) for at least 6 months~* Subject on basal human or analogue insulin, once daily (OD) or twice daily (BID) with or without metformin for at least 3 months or subject on premixed human or analogue insulin or self-mixed insulin regimen, containing 20-40% fast/rapid-acting component, OD or BID, with or without metformin, for at least 3 months~* HbA1c 7.0-10.0 % (both inclusive) by central laboratory analysis~* Body mass index (BMI) maximum 35.0 kg/m\^2~Exclusion Criteria:~* Treatment with oral antidiabetic drugs (OADs) (except metformin) within the last 8 weeks prior to Visit 1~* Treatment with thiazolidinediones (TZDs) or glucagon like peptide 1 (GLP-1) receptor agonists within 3 months prior to Visit 1~* Cardiovascular disease, within the last 6 months prior to Visit 1, defined as: stroke; decompensated heart failure New York Heart Association (NYHA) class III or IV; myocardial infarction; unstable angina pectoris; or coronary arterial bypass graft or angioplasty~* Uncontrolled treated/untreated severe hypertension (systolic blood pressure at least 180 millimetre (mm) mercury (Hg) and/or diastolic blood pressure at least 100 mmHg)~* Pregnancy, breast-feeding, the intention of becoming pregnant or not using adequate contraceptive measures according to local requirements~* Cancer and medical history of cancer (except basal cell skin cancer or squamous cell skin cancer)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IDegAsp BID (Type: EXPERIMENTAL): None
- BIAsp 30 BID (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of GTx-024 on Muscle Wasting (Cachexia) Cancer.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~To be eligible for participation in this study, subjects must meet all of the following criteria:~* have been diagnosed with Stage 2, 3 or 4 non-small cell lung cancer or Stage 2, 3 or 4 colorectal cancer or non-hodgkin's lymphoma or chronic lymphocytic leukemia or Stage 3 or 4 breast cancer.~* be prior to initiation of or between cycles of chemotherapy.~* have experienced greater than or equal to 2% weight loss from the highest patient reported weight in the 6 months prior to screening for Protocol G200502 (Wt = body weight)~  % weight loss = (Wt at screening - highest Wt in last 6 months) / highest Wt in last 6 months x 100%~* If surgery is part of the cancer treatment, screening for this study should be conducted at least 2 weeks (14 days) after surgery.~* have a life expectancy of \>6 months~* FEMALES - be clinically confirmed as postmenopausal~* MALES - over 45 years of age~* ECOG score ≤1~Exclusion Criteria:~Subjects with any of the following will NOT be eligible for enrollment in this study:~* history of active/uncontrolled congestive heart failure, chronic hepatitis, hepatic cirrhosis, or HIV infection~* Cardiovascular: No uncontrolled hypertension~* Positive screen for Hepatitis B consisting of HBsAg (Hepatitis B Surface Antigen), anti-HCV (Hepatitis C Antibody), hepatitis A antibody IgM, or HIV~* Currently taking testosterone, OXANDRIN® (oxandrolone), testosterone-like agents (such as DHEA, androstenedione, and other androgenic compounds, including herbals), or antiandrogens (Please note that previous therapy with testosterone and testosterone-like agents is acceptable with a 30 day wash-out. However, if the previous testosterone therapy was a long-term depot, within the past 6 months, the site should call the medical monitor for this study to determine appropriate washout period.)~* Currently taking megestrol acetate (MEGACE®), dronabinol (MARINOL®), or any prescription medication intended to increase appetite or treat unintentional weight loss

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): 1 mg GTx-024
- 2 (Type: EXPERIMENTAL): 3 mg GTx-024
- 3 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: NWP09 in Children With Attention Deficit Hyperactivity Disorder (ADHD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children aged 6 to 12 years with ADHD who require pharmacologic treatment for this condition~Exclusion Criteria:~* Other serious illnesses or conditions that would put the patient at particular risk for safety events or would interfere with treatment/assessment of ADHD

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Active (Type: EXPERIMENTAL): NWP09
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete